Literature DB >> 8199702

A case of allergic liver injury induced by tegafur.

M Baba1, T Shima, T Tanaka, M Nakayabu, H Hasegawa, S Suzuki, I Kusano.   

Abstract

A 51-year-old woman constitutionally susceptible to allergy presented with acute allergic liver injury. She was taking tegafur for treatment of carcinoma of the uterus. The acute liver injury appeared 3 weeks after the first drug administration. She had marked elevation of glutamic oxaloacetic transaminase (GOT) and glutamic pyruvic transaminase (GPT), moderate jaundice, and eosinophilia. The virus markers revealed hepatitis B surface antigen (HBsAg) (-) antibody to hepatitis B surface antigen (HBsAb) (+), and immunoglobulin M HA antibody (IgM HA Ab) (-). The laparoscopic and histologic findings were compatible with drug-induced liver injury. Further, the results of the lymphocyte stimulation test (LST) and challenge test by tegafur were positive. From the above findings, the liver injury was diagnosed to be an allergic reaction induced by tegafur. The hepatic function returned to normal about 20 days after tegafur administration was suspended. Allergic liver injury induced by tegafur is very rare. We report the case with a short review of the literature.

Entities:  

Mesh:

Substances:

Year:  1994        PMID: 8199702     DOI: 10.1007/bf01229081

Source DB:  PubMed          Journal:  J Gastroenterol        ISSN: 0944-1174            Impact factor:   7.527


  6 in total

1.  [A clinicopathological study of 11 patients with acute drug-induced hepatic failure].

Authors:  S Seki; Y Mizoguchi; S Saito; S Shiomi; Y Sakagami; H Sakaguchi; T Kuroki; S Harihara; K Kobayashi; T Monna
Journal:  Nihon Shokakibyo Gakkai Zasshi       Date:  1986-12

2.  [Analogs of pyrimidine nucleosides. I. N1-(alpha-furanidyl) derivatives of natural pyrimidine bases and their antimetabolities].

Authors:  S A Giller; R A Zhuk; M Iu Lidak
Journal:  Dokl Akad Nauk SSSR       Date:  1967-09-11

3.  [Effects and side effects of long-term administration of oral antitumor agents in patients with hepatocellular carcinoma--especially, relation to aggravation of liver function].

Authors:  K Ikeda; H Kumada; Y Arase; I Nakamura; K Chayama; N Murashima; K Takeuchi; M Nakajima; A Yoshiba; M Irimoto
Journal:  Nihon Shokakibyo Gakkai Zasshi       Date:  1987-10

4.  Hepatotoxicity of chemotherapeutic agents.

Authors:  M C Perry
Journal:  Semin Oncol       Date:  1982-03       Impact factor: 4.929

5.  Activation of Ftorafue [R,S-1-(tetrahydro-2-furanyl)-5-fluorouracil] to 5-fluorouracil and gamma-butyrolactone.

Authors:  J L Au; W Sadée
Journal:  Cancer Res       Date:  1980-08       Impact factor: 12.701

6.  Oral tegafur in the treatment of gastrointestinal tract cancers: a phase II study.

Authors:  S Palmeri; V Gebbia; A Russo; M G Armata; N Gebbia; L Rausa
Journal:  Br J Cancer       Date:  1990-03       Impact factor: 7.640

  6 in total
  3 in total

1.  An Unusual Case of Acute Liver Failure Caused by Adjuvant Oral Tegafur-Uracil with Folinate Therapy for Colon Cancer Patient: a Case Report.

Authors:  Masatsugu Hiraki; Toshiya Tanaka; Futa Koga; Akimasa Saito; Noriko Oza; Osamu Ikeda; Tatsuya Manabe; Atsushi Miyoshi; Kenji Kitahara; Seiji Sato; Hirokazu Noshiro
Journal:  J Gastrointest Cancer       Date:  2020-03

2.  Severe chronic active hepatitis induced by UFTR containing tegafur and uracil.

Authors:  F Kobayashi; T Ikeda; N Sakamoto; M Kurosaki; S Tozuka; S Sakamoto; T Fukuma; F Marumo; C Sato
Journal:  Dig Dis Sci       Date:  1995-11       Impact factor: 3.199

3.  Chronic active hepatitis and liver cirrhosis in association with combined tamoxifen/tegafur adjuvant therapy.

Authors:  S Maruyama; C Hirayama; J Abe; J Tanaka; K Matsui
Journal:  Dig Dis Sci       Date:  1995-12       Impact factor: 3.199

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.